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de Valdecilla, Santander, Spain; and 10Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, SpainIntroduction: Despite the high incidence of posttransplant diabetes mellitus (PTDM) among high-risk
recipients, no studies have investigated its prevention by immunosuppression optimization.
Methods: We conducted an open-label, multicenter, randomized trial testing whether a tacrolimus-based
immunosuppression and rapid steroid withdrawal (SW) within 1 week (Tac-SW) or cyclosporine A (CsA)
with steroid minimization (SM) (CsA-SM), decreased the incidence of PTDM compared with tacrolimus
with SM (Tac-SM). All arms received basiliximab and mycophenolate mofetil. High risk was deﬁned by age
>60 or >45 years plus metabolic criteria based on body mass index, triglycerides, and high-density
lipoprotein–cholesterol levels. The primary endpoint was the incidence of PTDM after 12 months.
Results: The study comprised 128 de novo renal transplant recipients without pretransplant diabetes (Tac-
SW: 44, Tac-SM: 42, CsA-SM: 42). The 1-year incidence of PTDM in each arm was 37.8% for Tac-SW, 25.7%
for Tac-SM, and 9.7% for CsA-SM (relative risk [RR] Tac-SW vs. CsA-SM 3.9 [1.2–12.4; P ¼ 0.01]; RR Tac-SM
vs. CsA-SM 2.7 [0.8–8.9; P ¼ 0.1]). Antidiabetic therapy was required less commonly in the CsA-SM arm
(P ¼ 0.06); however, acute rejection rate was higher in CsA-SM arm (Tac-SW 11.4%, Tac-SM 4.8%, and
CsA-SM 21.4% of patients; cumulative incidence P ¼ 0.04). Graft and patient survival, and graft function
were similar among arms.
Conclusion: In high-risk patients, tacrolimus-based immunosuppression with SM provides the best
balance between PTDM and acute rejection incidence.
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published online 11 July 2018PTDM is a frequent and severe complication of renaltransplantation (RT).1–3 With current immunosup-
pression regimens, the incidence of PTDM at 1 and
3 years is 20% and 30%, respectively.4 Importantly,
PTDM is an established risk factor for cardiovascular
disease and mortality, and accordingly, is associatedKidney International Reports (2018) 3, 1304–1315
A Torres et al.: Posttransplant Diabetes in High-Risk Recipients CLINICAL RESEARCHwith increased health care costs.5–8 However, few
studies have been designed to prevent this condition.9
RT recipients with risk factors for type 2 diabetes
most commonly develop PTDM after exposure to im-
munosuppressants.2,10,11 These risk factors include age
older than 45 years at the time of transplantation,
overweight, obesity, and hypertriglyceridemia, a
known marker of insulin resistance.12–17 For instance, a
retrospective study observed that each 50-mg/dl incre-
ment in serum levels of triglycerides determined a 30%
increase in the risk for PTDM.16 Moreover, the higher
the number of preexisting risk factors, the higher the
frequency of PTDM.11,15 Although the immunosup-
pressive regimen explains 74% of the risk of PTDM,18,19
the best immunosuppressive approach in patients at risk
for developing PTDM is not yet deﬁned.
Early SW posttransplantation is associated with a
reduction in the RR of PTDM.20,21 However, 2 recent
studies in patients treated with tacrolimus yielded
conﬂicting results. Although SW at day 8 reduced
PTDM at 1 year from 39% in maintenance steroid pa-
tients to 24%,22 others observed no differences after 5
years between patients with early SW and chronic
maintenance steroids.23 Thus, the role of early SW in
patients at risk for PTDM is not yet established.
Tacrolimus reduces insulin secretion both in vitro and
in vivomore potently than CsA.24,25 In the DIRECT trial,
the only study comparing CsA and tacrolimus with
PTDM as the primary endpoint, CsA was superior to
tacrolimus.25 Furthermore, the effects of tacrolimus are
exacerbated in patients with type 2 diabetes suscepti-
bility, a phenomenon not observed with CsA.16,26,27
This interaction has also been demonstrated in Zucker
rats, in which tacrolimus induces higher rates of dia-
betes in obese and insulin-resistant animals than CsA,
but not in nonobese animals.28 Conversion from tacro-
limus to CsA in both insulin-resistant rodents and pa-
tients reverses diabetes in 35% to 50% of cases,29–31
improving beta-cell secretion, proliferation, and insu-
lin gene expression in vivo.29 We, therefore, reasoned
that CsA may be an alternative to tacrolimus to decrease
early beta-cell damage in patients at high risk for PTDM.
The primary objective of this open, randomized
controlled trial was to investigate the incidence of
PTDM in high-risk patients under a tacrolimus-based
immunosuppression and rapid SW within 1 week, or
CsA with SM, compared with tacrolimus and SM.METHODS
Study Design
This study was an investigator-driven, open-label,
multicenter, prospective, randomized phase IV clinical
trial of 12-month duration in which de novo RT patientsKidney International Reports (2018) 3, 1304–1315with a low immunological risk and high risk for PTDM
were randomized 1:1:1 to 3 arms: tacrolimus and rapid
SW in 1 week (Tac-SW), CsA with SM (CsA-SM), and
tacrolimus with SM (Tac-SM) as a control group. All
groups received induction with basiliximab. All pa-
tients signed an informed consent, and the study was
approved by the ethics and clinical research committee
of each participating center.
Study Population
We included patients with end-stage renal disease who
received a ﬁrst RT in the absence of (i) pretransplant
diabetes, deﬁned as baseline blood glucose $126 mg/dl
or treatment with hypoglycemic medication; (ii)
immunological risk deﬁned by panel-reactive antibody
score <50% plus investigator’s criteria; and (iii)
infection by hepatitis C and/or B viruses. Additionally,
at least 1 of the following “metabolic criteria” were
required: (i) recipient age $60 years, or (ii) recipient
age between 45 and 59 years plus 1 of the following
criteria: (i) pretransplant triglyceride level$200 mg/dl,
(ii) body mass index >27 kg/m2 plus triglycerides
>150 mg/dl, or (iii) high-density lipoprotein
cholesterol <40 mg/dl in men or 50 mg/dl in women
plus triglycerides >150 mg/dl.
We excluded patients who received a graft that, in
the opinion of the investigator, required a delay in the
initiation of calcineurin inhibitors supported by
induction with thymoglobulin. We also excluded
patients with double kidney transplants or transplants
of a kidney plus another organ.
Randomization, Arms, and Interventions
After signing the informed consent, patients were
randomized 1:1:1 with a computerized algorithm
generated in the Research Unit of Hospital Uni-
versitario de Canarias.
 Tac-SW arm: tacrolimus (Prograf) 0.15 mg/kg per day
p.o. in 2 separate doses to maintain trough levels of 8
to 12 ng/ml in the ﬁrst month, and mycophenolate
mofetil (MMF; Cell Cept) 2 g/d p.o. Methyl-
prednisolone 0.5 g i.v. intraoperatively and 125 mg
on day 1; prednisone 30 mg p.o. on days 2 and 3, 20
mg on day 4, 15 mg on day 5, 10 mg on day 6, 5 mg
on day 7, and then discontinuation.
 Tac-SM arm: tacrolimus and MMF following the same
schedule as in arm 1. Intraoperative and day 1
methyl-prednisolone as in arm 1; prednisone 0.3 mg/
kg per day p.o. from day 2 to 7 (never >20 mg/d), 0.2
mg/kg per day from day 8 to 14 (never >15 mg/d),
0.15 mg/kg per day from day 15 to 21 (never >10
mg/d), 0.1 mg/kg per day from day 22 to 28 (never
>7.5 mg/d), and then 5 mg/d until 5 months, with
subsequent gradual discontinuation over 4 weeks.1305
CLINICAL RESEARCH A Torres et al.: Posttransplant Diabetes in High-Risk Recipients CsA-SM arm: Cyclosporine A microemulsion (Neoral)
(CsA) 5 mg/kg per day p.o. to maintain C0 levels of
150–200 ng/ml the ﬁrst month, and MMF and steroids
following the same schedule as arm 2.
Basiliximab, 20 mg i.v. on days 0 and 4, was
administered in all arms. In the tacrolimus arms, the
MMF was reduced to 1 g/d from the ﬁrst month, but in
the CsA-SM arm, the target was a dose of 2 g/d.
In all 3 arms, tacrolimus and CsA levels were
reduced from the ﬁrst month according to usual clinical
practice until 1 year, when target levels of tacrolimus
were established at 5 to 8 ng/ml, and those of CsA at
100–150 ng/ml.
Conversion from CsA to tacrolimus was contem-
plated in CsA-SM patients who developed acute rejec-
tion as per the investigator’s criteria. Likewise,
conversion from a calcineurin inhibitor to mammalian
target of rapamycin inhibitor was done when consid-
ered necessary from clinical practice, such as in severe
nephrotoxicity, neoplasia, or viral infection. Steroids
were maintained or re-introduced at low doses (5 mg/d
of prednisone) in the case of acute rejection, conversion
to mammalian target of rapamycin inhibitor, or if it was
considered clinically necessary to balance immuno-
suppression, at the investigator’s discretion, such as in
the event of MMF dose reduction due to leukopenia or
diarrhea.
Biopsy-proven acute rejection was classiﬁed
according to the Banff 2007 criteria.32 Rejections were
treated with 3 boluses of 500 mg/d of i.v. methyl-
prednisolone. Corticoresistant rejections were treated
with rabbit thymoglobulin. Acute humoral rejections
were treated with 3 boluses of methyl-prednisolone
and plasmapheresis, plus i.v. Igs and/or rituximab.
Universal pneumocystis jirovecii prophylaxis was
given with cotrimoxazole, and cytomegalovirus pro-
phylaxis in at-risk patients according to the protocol of
each participating center.
In case of hyperglycemia in the postoperative
period, rapid insulin therapy was initiated when fast-
ing capillary blood glucose was $180 mg/dl. During
the study, patients who developed diabetes received
antidiabetic therapy based on the international guide-
lines available at the start of the study.33
Evaluation
In addition to routine laboratory determinations, fast-
ing blood glucose was measured each day on days 3
through 7, as well as at months 3, 6, and 12, and
HbA1c at 3 and 12 months posttransplantation. A
standard oral glucose tolerance test (OGTT) of 75 g
glucose was performed at 3 and 12 months, except in
those patients who had already developed PTDM.
Fasting insulin levels were measured at 3 and 121306months posttransplantation as described,34 and the
McAuley index was calculated as an estimate of insulin
resistance.35 The glomerular ﬁltration rate was esti-
mated by MDRD 4, and proteinuria was quantiﬁed
either in 24-hour urine or as the protein/creatinine
ratio in the ﬁrst voided morning sample by standard
methods.Efﬁcacy and Safety Variables
The primary endpoint was the presence of PTDM based
on the American Diabetes Association criteria.36 For the
purposes of the study, patients were classiﬁed based on
2 criteria: criterion 1, those in whom fasting blood
glucose levels were $126 mg/dl, HbA1c $6.5%, or
received hypoglycemic treatment; criterion 2, which
includes all the cases classiﬁed by criterion 1 plus those
in whom PTDM was diagnosed only by the OGTT
(blood glucose levels at 120 minutes $200 mg/dl).36
Glucose intolerance was deﬁned as blood
glucose $140 mg/dl and <200 mg/dl 120 minutes after
the OGTT.36
The major safety variables were the biopsy-proven
acute rejection rate, estimated glomerular ﬁltration
rate, proteinuria, and graft and patient survival.Statistical Analysis: Sample Size
Both intention-to-treat and per-protocol analyses were
performed. We used the 1-way analysis of variance test
to compare continuous variables between groups. The
proportion of patients in each study arm with PTDM or
glucose intolerance was compared by c2 test and also
expressed as RR with 95% conﬁdence interval. The
Kaplan-Meier and log-rank test were used to compare
graft and patient survival, as well as the cumulative
incidence of acute rejection.
At study design, the deﬁnition of PTDM varied
considerably between studies, making meaningful
comparisons of its incidence difﬁcult. Also, few data on
high-risk patients were available. With these limita-
tions, the sample size was calculated based on previous
publications in which the rate of PTDM in patients on
tacrolimus with rapid SW was 8%20 versus 27% in
patients on tacrolimus with maintenance steroids in a
clinical trial conducted in Spain.37 For high-risk
patients, a similar 2.7 proportional reduction was
assumed. Thus, with a statistical power of 80% and a
2-tailed signiﬁcance level (alpha) of 0.05, 64 subjects
per group were required. For CsA, we expected a
reduction in PTDM of at least 50%, as observed in the
Symphony study.38 Therefore, we planned to include a
similar number in this group. Assuming a 10% loss rate
we started the study with the intention of including
210 subjects, 70 per arm.Kidney International Reports (2018) 3, 1304–1315
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had completed the study was planned.
RESULTS
Patients Included
Eight transplant centers participated in the study,
which began on February 23, 2010. In the intermediate
analysis, a higher frequency of acute rejection was
observed in the CsA arm (Tac-SW 14%, Tac-SM 3%,
and CsA-SM 20%). The Safety Committee decided to
stop recruitment but continue with the patients already
recruited until the end of the study. Therefore, until
February 5, 2014, a total of 128 patients were recruited
(Figure 1).
Demographics of Patients and Donors
More than 90% of the recipients were white and none
had a panel-reactive antibody score >25% (Table 1).
All donors were deceased except 1 living donor. The
arms were comparable except for a greater number of
HLA mismatches in the CsA-SM versus Tac-SW arm.
Although nonsigniﬁcant, a family history of diabetes
was 2- to 3-fold more common in the CsA-SM arm. The
rate of delayed graft function was high (52%), corre-
sponding to the high frequency of expanded criteria
donors (60%).
Exposure to Immunosuppressants
Supplementary Table S1 shows the tacrolimus and CsA
trough levels in each arm throughout the study, whichAssessed for eligibility
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Kidney International Reports (2018) 3, 1304–1315remained slightly above the planned range in the ﬁrst 3
months. There were no signiﬁcant differences in
tacrolimus levels between Tac-SW and Tac-SM arms.
At study end, 85.4% of Tac-SW, 49% of Tac-SM, and
34.2% of CsA-SM patients were free of corticosteroids.
Mean cumulative prednisolone equivalent doses were
as follows: Tac-SW 1163  1064, Tac-SM 2210  1000,
and CsA-SM 2620  1084 mg (Tac-SW vs. Tac-SM or
CsA-SM, P < 0.001).
MMF doses were signiﬁcantly higher in the CsA arm
throughout the study (Tac-SW 0.95  0.3, Tac-SM
0.97  0.3, and CsA-SM 1.4  0.4 g/d at study end;
P < 0.001).
Primary Efﬁcacy Variable
Early Alterations in Glucose Metabolism
The proportion of patients requiring insulin therapy
during their index hospitalization was 31.0%, 35.7%,
and 26.2% for Tac-SW, Tac-SM, and CsA-SM arms,
respectively (P ¼ 0.5). From the ﬁrst days after trans-
plantation to the thirdmonth, fasting glucose levelswere
signiﬁcantly lower in the CsA-SM arm versus Tac-SW or
Tac-SM arms (Figure 2a). At 3 months, the proportion of
patients with PTDM according to criterion 1 or 2 was
lower in CsA-SM arm versus Tac-SW and Tac-SM arms,
although of borderline signiﬁcance (Figure 2b and c).
Alterations in Glucose Metabolism at Study End
The proportion of patients with PTDM according to
criterion 1 or 2 was lower in the CsA-SM arm (Table 2
and Figure 3a and b). Four patients in the Tac-SW, 4 indelay 
tion
blems
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f I.C. n = 3
M
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IS
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Tac-SW: DFG n = 2; graft loss n = 1
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ine A and steroid minimization; I.C., inclusion criteria; DFG: death with
, tacrolimus and rapid steroid withdrawal.
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Table 1. Baseline characteristics of the 3 study arms (original assigned groups)
Variable Tac-SW (n [ 44) Tac-SM (n [ 42) CsA-SM (n [ 42) All (n [ 128) P
Age (yr) 61.2  7.6 61.6  7.3 60.2  8.3 61  7.7 0.7
Gender (% female) 11 (25) 12 (28.6) 12 (28.6) 35 (27.3) 0.9
Race 41W/1NA/2H 38W/1NA/3H 39W/1BR/1NA/1H 118W/1BR/3NA/6H 0.8
Dialysis duration (mo) 37.9  30 28.6  23.6 33  26.3 33.2  26.8 0.3
Donor age (yr) 62.1  10.4 62.9  8.9 61.6  10 62.2  9.8 0.8
Donor creatinine (mg/dl) 0.8  0.3 0.9  0.4 0.9  0.3 0.9  0.3 0.6
Expanded criteria donor (%) 25 (57) 26 (62) 26 (62) 77 (60) 0.9
Cold ischemia time (h) 16.8  5.5 18.2  5.4 17.3  6.4 17.4  5.8 0.6
HLA-A-B-DR mismatches 3.6  1.2 4  0.9 4.2  1.1a 3.9  1.1 0.01
PRA (>0 and <25%) 3 0 1 4 0.3
Delayed graft function (%) 17/44 (38.6) 24/42 (57.1) 25/42 (59.5) 66/128 (51.5) 0.09
Body mass index (kg/m2) 26.9  3.7 27.9  3.7 27.9  4.1 27.6  3.8 0.4
Family history of diabetes (%) 3 (8)
Unknown: 6
4 (12)
Unknown: 9
9 (23)
Unknown: 3
16 (14.5)
Unknown: 18
0.2
Fasting glucose (mg/dl) 91.9  13.2 97.7  14.3 91.9  13.9 93.9  14 0.09
HbA1c (%) 5.3  0.5 5.4  0.3 5.3  0.4 5.3  0.4 0.8
Triglycerides (mg/dl) 184.3  11.9 199.3  92 209.7  109 197.6  105.8 0.5
Total cholesterol (mg/dl) 165.9  48 162.8  39.3 179.4  42.5 169.4  43.8 0.2
HDL cholesterol (mg/dl) 41  14.4 42.5  12.1 42.2  15.3 41.9  13.9 0.9
LDL cholesterol (mg/dl) 98.5  36.6 90  37.5 103.8  36 97.6  36.8 0.3
BR, Black race; W, White race; CsA-SM, cyclosporine A and steroid minimization; H, Hispanic; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NA, North African; PRA, panel-
reactive antibodies; Tac-SM, tacrolimus and steroid minimization; Tac-SW, tacrolimus and rapid steroid withdrawal.
aP < 0.05 CsA-SM versus TAC-SW.
CLINICAL RESEARCH A Torres et al.: Posttransplant Diabetes in High-Risk Recipientsthe Tac-SM, and 7 in the CsA-SM arm, were excluded
from criterion 2 because an OGTT could not be per-
formed. The major differences were observed between
Tac-SW versus CsA-SM arms (RR 10.2 [1.4–75.3];
P ¼ 0.004 for criterion 1; and RR 3.9 [1.2–12.4];
P ¼ 0.01 for criterion 2). Differences between Tac-SM
and CsA-SM did not reach statistical signiﬁcance (RR
5.8 [0.7–46.3]; P ¼ 0.1 for criterion 1; and RR 2.7
[0.8–8.9]; P ¼ 0.1 for criterion 2). Fewer patients
required treatment with hypoglycemic drugs in the
CsA-SM arm, although of borderline signiﬁcance
(Table 2 and Figure 3c).
There were no signiﬁcant differences between arms
in weight gain, fasting blood glucose, HbA1c levels, or
insulin sensitivity index (Table 2). Blood pressure, lipid
levels, and the proportion of patients being treated
with statins, renin-angiotensin system inhibitors, ace-
tylsalicylic acid, or beta-blockers were comparable in
all 3 arms (Table 2).
The per-protocol analysis showed similar results.
The incidence of PTDM at study end was 35% (14/40),
25% (9/36), and 7.7% (2/26), in Tac-SW, Tac-SM, and
CsA-SM arms, respectively (P ¼ 0.04). Treatment with
hypoglycemic drugs was required in 20.0%, 16.7%,
and 3.8% of patients in Tac-SW, Tac-SM, and CsA-SM
arms, respectively (P ¼ 0.1).
Changes in Glucose Metabolism Between 3 and 12
Months
Compared with 3 months, the proportion of patients
with euglycemia increased at 12 months in all arms
(Figure 4). In the Tac-SW arm, the proportion of1308patients with glucose intolerance decreased but that of
PTDM did not change. In the Tac-SM arm, both
glucose intolerance and PTDM diminished. In the CsA-
SM arm, PTDM diminished by improving to glucose
intolerance at study end.
Glucose Metabolism After Conversion From CsA to
Tacrolimus
A conversion was performed in 9 patients after biopsy-
proven acute rejection, 5 in the ﬁrst 3 months
(Supplementary Table S2). None had PTDM at the time
of conversion by criterion 1 and only 1 case showed
PTDM at study end (Supplementary Table S2).
Glucose Metabolism After Conversion From
Calcineurin Inhibitors to Mammalian Target of
Rapamycin Inhibitors
A conversion was performed in 1 patient from the Tac-
SW arm, 3 from Tac-SM, and 3 from CsA-SM, all to
everolimus (Supplementary Table S3). In 5 cases, con-
version was due to impaired renal function and inter-
stitial ﬁbrosis and tubular atrophy lesions in the graft
biopsy, with no evidence of acute rejection; in 2 cases,
conversion was performed after a malignancy was
diagnosed (squamous cell carcinoma and non-Hodgkin
lymphoma, respectively). After conversion, no patient
developed PTDM (Supplementary Table S3).
Acute Rejection
The proportion of patients in the CsA-SM arm with
acute rejection was higher than in the Tac-SW and
Tac-SM arms (Table 2). A total of 3 patients had 2
episodes of biopsy-proven acute rejection during theKidney International Reports (2018) 3, 1304–1315
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Figure 2. Glucose homeostasis alterations 3 months after transplantation in each study arm. (a) Fasting plasma glucose. (b) Proportion of
patients with posttransplant diabetes (PTDM) according to criterion 1. (c) Proportion of patients with PTDM according to criterion 2. CsA-SM,
cyclosporine A and steroid minimization; Tac-SM, tacrolimus and steroid minimization; Tac-SW, tacrolimus and rapid steroid withdrawal. *P <
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Thus, the cumulative incidence of acute rejection was
signiﬁcantly higher in the CsA-SM arm (P ¼ 0.04;
Figure 5). Steroid-resistant acute rejections requiring
treatment with rabbit thymoglobulin were more
frequent in the CsA-SM arm (Table 2). The 2 cases of
grade II acute rejection and the 2 cases of biopsy-
proven acute humoral rejection were in the CsA-SM
arm. Only 1 graft was lost due to acute rejection, in
the CsA-SM arm.
Graft and Patient Survival
Uncensored-death graft survival was similar between
study arms (Supplementary Figure S1A). During the
study, a total of 10 grafts were lost: 3 in the Tac-SW
arm (hemolytic uremic syndrome n ¼ 1, death n ¼ 2);
3 in the Tac-SM arm (graft thrombosis n ¼ 1, pyelo-
nephritis of the graft n ¼ 1, death n ¼ 1); and 4 in the
CsA-SM arm (graft thrombosis n ¼ 1, acute rejection
n ¼ 1, death n ¼ 2).
Kidney International Reports (2018) 3, 1304–1315Patient survival was similar in all 3 arms
(Supplementary Figure S1B). During the study, 5 pa-
tients died: 2 in the Tac-SW arm (sudden death 1,
cytomegalovirus pneumonia 1), 1 in the Tac-SM arm
(shock of uncertain origin), and 2 in the CsA-SM arm
(sudden death 1, Pseudomonas aeruginosa pneumonia
plus sepsis 1).
Renal Function
Estimated glomerular ﬁltration rate and proteinuria
at the end of the study were not different between
arms (Table 2).
Adverse Events
Table 3 summarizes the adverse effects. A trend to a
higher incidence of acute graft pyelonephritis in the
CsA-SM arm was observed (P ¼ 0.07). However, the
overall incidence of infectious events and proportion of
affected patients were not different among the 3 arms.
The proportion of patients with severe adverse events1309
Table 2. Metabolic, cardiovascular, and renal function data in each arm at study end (1 year)
Variable Tac-SW (n [ 41) Tac-SM (n [ 39) CsA-SM (n [ 38) P
BMI (kg/m2) 27.3  4 27.9  4 28.1  4.6 0.6
Weight increase from baseline (kg) 0.7  7 -0.2  6 1.5  6.7 0.5
Fasting glucose (mg/dl) 104.2  17.5 100.6  14.7 96.8  16.1 0.1
HbA1c (%) 5.7  0.5 5.8  0.5 5.5  0.4 0.1
Insulin sensitivity (McAuley Index) 4.7  1.4 4.5  1.1 4.7  1.2 0.7
PTDM (%):
-Criterion 1 (fasting glucose, HbA1c; medication use) 11/41 (26.8) 6/39 (15.4) 1/38 (2.6) 0.01
-Criterion 2: criterion 1 þ unmasked PTDM 14/37 (37.8) 9/35 (25.7) 3/31 (9.7) 0.03
Oral antidiabetics and/or insulin therapy (%) 8 (20) 6 (15.4) 1 (2.6) 0.06
Insulin therapy 2 (5) 1 (2.6) 0 0.4
Acute rejection (%) 5/44 (11.4) 2/42 (4.8) 9/42 (21.4) 0.07
Corticoresistant acute rejection (%) 1/44 (2.3) 1/42 (2.4) 4/42 (9.5) 0.2
Serum creatinine (mg/dl) 1.6  0.7 1.5  0.5 1.7  0.6 0.3
eGFR (ml/min per 1.73 m2) 51.9  21 47.4  14 44.6  21 0.2
Proteinuria (mg/d) 208  269 241  387 343.2  558 0.4
Triglycerides (mg/dl) 159.4  94 145.6  53 160.8  84 0.7
Total cholesterol (mg/dl) 169.1  31 178.2  33.6 169  33.4 0.4
HDL cholesterol (mg/dl) 44.8  14 49.3  16.9 48.4  16.6 0.5
LDL cholesterol (mg/dl) 94  27 95.4  26.5 88.7  25.7 0.5
Patients on ACEI/ARA (%) 19 (46) 17 (43.5) 15 (39.5) 0.8
Patients on statins (%) 23 (56) 24 (61.5) 28 (78) 0.2
Patients on ASA (%) 22 (54) 19 (49) 20 (53) 0.9
Patients on beta-blockers (%) 16 (39) 18 (46) 21 (55) 0.4
Systolic BP (mm Hg) 135.4  16 134  14 136.3  17 0.8
Diastolic BP (mm Hg) 76.7  8.9 74.6  9.8 76.6  10.3 0.6
ACEI, angiotensin-converting enzyme inhibitor; ARA, angiotensin II receptor antagonists; ASA, acetylsalicylic acid; BMI, body mass index; BP, blood pressure; CsA-SM, cyclosporine A
and steroid minimization; eGFR, estimated glomerular ﬁltration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTDM posttransplant diabetes mellitus; Tac-SM,
Tacrolimus and steroid minimization; Tac-SW, tacrolimus and rapid steroid withdrawal.
CLINICAL RESEARCH A Torres et al.: Posttransplant Diabetes in High-Risk Recipients(those shown in Table 3 plus death, graft loss, and
biopsy-proven acute rejection) was comparable in the
Tac-SW and Tac-SM arms, but signiﬁcantly higher in
the CsA-SM arm (38.6%, 42.9%, and 71.4%, respec-
tively; P ¼ 0.005).
DISCUSSION
This study shows that in patients with a high risk for
PTDM, tacrolimus-based immunosuppression, admin-
istered with basiliximab and MMF plus SM, provides
the best balance between PTDM and acute rejection
incidence. Under a similar regimen, rapid SW did not
further reduce the incidence of PTDM and was asso-
ciated with a slight increase in biopsy-proven acute
rejection (BPAR). CsA-based immunosuppression with
SM was associated with a larger decrease in PTDM but
at the expense of increasing BPAR that led to the
interruption of the trial.
This randomized controlled trial was designed to
balance the risk-beneﬁt associated with the use of ste-
roids, tacrolimus, or cyclosporin A in high-risk pa-
tients for PTDM. Based on previous reports showing
that SW reduced the risk for PTDM,20–22 we aimed to
test whether a rapid SW at day 8 was superior to SM in
terms of PTDM incidence without affecting efﬁcacy
deﬁned by BPAR rate. The inclusion of a CsA group
was based on the established lower beta-cell toxicity of1310CsA in a situation of insulin resistance.16,26–28 We chose
a CsA dose between the standard and low-dose groups
of the Symphony trial,38 plus basiliximab. Thus, we
could test whether the use of CsA in a situation of older
recipients and immunosenescense39 decreases the inci-
dence of PTDM without affecting efﬁcacy.
Mean tacrolimus and CsA levels were in the upper
limit of the planned range, especially during the ﬁrst 3
months, which might reﬂect the conservative approach
of investigators in this type of study (Supplementary
Table S1).
A relevant ﬁnding of this study is that in patients at
high risk for developing PTDM, tacrolimus-based
immunosuppression with SM results in a lower than
anticipated 1-year incidence of PTDM with a low rate
of BPAR. The observed 26% incidence compares
favorably with the reported 44% to 56% in high-risk
patients,15,16 and falls within the 17% to 39%
observed in the transplant population at large.16,22,40
Additionally, PTDM was manageable because only 1
patient required insulin therapy at study end and the
mean HbA1c was <7% (6.4  0.6; 95% conﬁdence
interval 5.7%–7.0%). Finally, the consistent improve-
ment in glucose metabolism from 3 to 12 months due
to decreasing immunosuppression (Figure 4) un-
derscores the partial reversibility of tacrolimus-
induced dysglycemia.4,29,30,31Kidney International Reports (2018) 3, 1304–1315
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Figure 3. Glucose homeostasis alterations 12 months after transplantation (end of study) in each study arm. (a) Proportion of patients with
posttransplant diabetes (PTDM) according to criterion 1. (b) Proportion of patients with PTDM according to criterion 2. (c) Proportion of patients
requiring treatment with hypoglycemic drugs. CsA-SM, cyclosporine A and steroid minimization; Tac-SM, tacrolimus and steroid minimization;
Tac-SW, tacrolimus and rapid steroid withdrawal. *P < 0.01; **P < 0.05; ***P ¼ 0.06.
A Torres et al.: Posttransplant Diabetes in High-Risk Recipients CLINICAL RESEARCHCompared with SM, rapid SW in tacrolimus-treated
patients did not provide a further reduction of
PTDM. The associated slight increase in BPAR (11.4%
vs. 4.8%), a speciﬁc risk factor of PTDM due to the
concomitant use of high corticosteroid doses,1–3,40 may
at least partly explain this ﬁnding. In fact, 3 of the 5
patients with BPAR developed PTDM. Furthermore,
withdrawal of 5 mg/d of prednisone did not improve
the insulin sensitivity index in RT recipients.41 Indeed,
insulin sensitivity index values at study end were
comparable between arms (Table 2).
Although in the population at large, CsA is associ-
ated with a lower risk of PTDM than tacrolimus,25,38
this is the ﬁrst study showing the superiority of CsAKidney International Reports (2018) 3, 1304–1315in high-risk recipients (Table 2). This was observed
from the ﬁrst weeks of the study (Figure 2), therefore
minimizing the exposure to early glucotoxicity, a risk
factor for PTDM at 1 year.42 At study end, the 21.4%
rate of BPAR was slightly lower than the 24% to 26%
observed in the CsA arms of the Symphony trial.38
However, it was at least twice that of the tacrolimus
arms (Table 2, Figure 5), leading to the interruption of
the trial. CsA exposure in the present study, especially
in the early posttransplant period, was lower than in
controlled trials, showing a similar efﬁcacy between
tacrolimus and CsA.25,43 Furthermore, SM in this
context may have added a further risk of under-
immunosuppression. A contributing factor to the1311
Figure 4. Evolution of glucose homeostasis alterations in each study arm from 3 to 12 months after transplantation. CsA-SM, cyclosporine A and
steroid minimization; IGT, impaired glucose tolerance; PTDM, posttransplant diabetes; Tac-SM, tacrolimus and steroid minimization; Tac-SW,
tacrolimus and rapid steroid withdrawal.
CLINICAL RESEARCH A Torres et al.: Posttransplant Diabetes in High-Risk Recipientssuboptimal efﬁcacy of CsA in our aging population may
have been the higher immunogenicity of a consistent
proportion of grafts belonging to expanded criteria
donors with delayed graft function39 (Table 1).1.0
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Figure 5. Cumulative incidence of biopsy-proven acute rejection (BPAR) in
steroid minimization; Tac-SM, tacrolimus and steroid minimization; Tac-SW
1312Although conversion from CsA to tacrolimus in
prevalent RT recipients does not affect glucose meta-
bolism,44,45 the effect of early conversion is not well
established. In this study, a conversion was performed8 10 12
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each study arm. Log-rank test P ¼ 0.04. CsA-SM, cyclosporine A and
, tacrolimus and rapid steroid withdrawal.
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Table 3. Number of adverse events and proportion of affected/at-
risk patients at study end
Tac-SW Tac-SM CsA-SM Total P
Cardiovascular
Sudden death 1 0 1 2 0.6
IHD 0 1 2 3 0.3
Stroke 0 1 0 1 0.3
Total no. cardiovascular events 1 2 3 6 0.6
Patients affected/at risk (%) 1/44
(2.3)
2/42
(4.8)
3/42
(7.1)
6/128
(4.7)
0.6
Infections
Pneumonia 1 1 2 4 0.8
CMV 7 6 12 25 0.2
BKV 4 2 3 9 0.7
Acute pyelonephritis 2 6 1 9 0.07
Bacteriemia 1 5 2 8 0.2
Total no. infectious events 15 20 20 55 0.3
Patients affected/at risk (%) 10/44
(22.7)
11/42
(26.2)
14/42
(33.3)
35/128
(27.3)
0.5
Neoplasia
Native kidney 0 1 0 1 0.4
PTLD 0 0 1 1 0.4
Squamous carcinoma 0 0 1 1 0.4
Total no. neoplasia 0 1 2 3 0.3
Patients affected/at risk (%) 0/44
(0)
1/42
(2.4)
2/42
(4.8)
3/128
(7.1)
0.3
BKV, BK virus infection; CMV, cytomegalovirus infection; CsA-SM, cyclosporine A and
steroid minimization; IHD, ischemic heart disease; PTLD, posttransplant lymphoproli-
ferative disease; Tac-SM, tacrolimus and steroid minimization; Tac-SW, tacrolimus and
rapid steroid withdrawal.
A Torres et al.: Posttransplant Diabetes in High-Risk Recipients CLINICAL RESEARCHin 9 patients, 5 during the ﬁrst 3 months (Supplementary
Table S2). Interestingly, only 1 patient developed PTDM
10 months later. This ﬁnding is in agreement with the
results of a prospective randomized trial comparing CsA
and tacrolimus46 showing a 48% reduction of insulin
secretion at week 3 in patients receiving tacrolimus, and
this divergence disappeared from 3 weeks onward.
Therefore, protecting the beta-cell of high-risk patients
during the ﬁrst month by the temporal substitution of
tacrolimus by CsA, under rabbit thymoglobulin or at a
higher exposure than the present study, or the use of
new regimens facilitating early lower exposure to
tacrolimus, may further decrease the incidence of PTDM
without decreasing efﬁcacy. Alternatively, and based on
the results of a recent randomized trial,31 a tacrolimus-
based regimen with SM may be used to prevent acute
rejection during the early posttransplant period and to
replace tacrolimus with CsA in patients with inade-
quately controlled PTDM in the maintenance phase.
However, this should be demonstrated in future studies
with an ad hoc design.
Adverse events were not signiﬁcantly different be-
tween the study arms (Table 3). A nonsigniﬁcant trend to
increased acute graft pyelonephritis and secondary uro-
sepsis was observed in the tacrolimus with SM arm.
Unfortunately, differences in other confounding factors,
like days of indwelling bladder catheterization or double-
J stents, could not be determined; however, the totalKidney International Reports (2018) 3, 1304–1315number of infections was comparable among arms. The
recruited cohort showed a relatively high incidence of
graft loss and patient death by current standards but this
has to be interpreted in the context of a mean recipient
age of 60 years and a high proportion of expanded criteria
donor and delayed graft function (Table 1).
This study has limitations. First, the recruitment was
prematurely stopped for safety reasons. Therefore, the
study was not powered to demonstrate the observed
noninferiority of Tac-SM arm versus Tac-SW in terms of
PTDM. Thus, the comparison between these arms should
be taken with caution. Second, because an OGTT at the
time of transplantation could not be performed, we may
have missed 3% to 8% of unrecognized diabetes that
could be higher in our at-risk population.47,48 A pre-
transplant OGTT to rule out occult diabetes could have
been of relevance, but it is impractical in a deceased-donor
setting. However, we adopted the term PTDM avoiding
new-onset diabetes, to simply describe persistent post-
transplant hyperglycemia not present at transplantation.49
In fact, differences between arms in posttransplant hy-
perglycemia (criterion 1) were similar to that observed
after including the OGTT (criterion 2) (Table 2). Our
population was mainly white and of low immunological
risk, making the results not representative of other
transplant populations. Finally, donor-speciﬁc antibody
data were not planned when the study was designed and
thus were not widely collected for patients with BPAR.
In conclusion, tacrolimus-based immunosuppres-
sion, administered with basiliximab and MMF plus SM,
provides the best balance between PTDM and acute
rejection incidence in high-risk patients. Rapid SW or
CsA-based immunosuppression showed no advantages
or increased the risk of acute rejection.DISCLOSURE
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SUPPLEMENTARY MATERIAL
Table S1. Trough blood levels of tacrolimus and
cyclosporine A (CsA) at each study point.1313
CLINICAL RESEARCH A Torres et al.: Posttransplant Diabetes in High-Risk RecipientsTable S2. Glucose metabolism before and after conversion
from cyclosporine A (CsA) or tacrolimus to everolimus.
Table S3. Glucose metabolism before and after conversion
from cyclosporine A (CsA) or tacrolimus to everolimus.
Figure S1. Noncensored graft (A) and patient survival (B) in
each study arm. Log-rank test P ¼ 0.9 and P ¼ 0.8,
respectively. CsA-SM, cyclosporine A and steroid minimi-
zation; Tac-SM, tacrolimus and steroid minimization; Tac-
SW, tacrolimus and rapid steroid withdrawal.
Supplementary material is linked to the online version of
the paper at www.kireports.org.REFERENCES
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